Board of Directors

Jean Combalbert  (Non-Executive Chairman)
Jean Combalbert is the CEO of Euroscreen which he joined in April 2006, with more than 20 years experience in pharmaceutical and biotech companies. Dr Combalbert received his PhD in pharmacy from the University of Marseille, France. Following post-doctoral research on pharmacokinetics and metabolism at the French public research institute, INSERM, he joined the pharmaceutical industry where he held senior positions at Sanofi then with Galderma in France and USA. Prior to joining Euroscreen, he was Vice-President, Pharmaceutical Development at Proteus SA and then Chairman & CEO of Entomed SA.

Edmond Godfroid (Managing Director & Chief Scientific Officer)

Pierre Detrixhe (Non-Executive Director)
Pierre Detrixhe is Investment Manager at “Groupe Capital & Croissance”. He manages a fund (“Financière Spin-off Luxembourgeoise”) providing early-stage financings to technological start-ups. Prior to that, he worked as technology transfer officer and scientist in the area of biotechnology. He holds a master in bioengineering and a master in Management.

Chris Buyse (Non-Executive Director)
Chris Buyse is the former Chief Financial Officer of Thrombogenics NV and has more than 20 years’ experience in international company finance, including running and establishing best financial practice. Before ThromboGenics, as CFO of the Belgian biotechnology company CropDesign, he coordinated its acquisition by BASF in early 2007. Mr Buyse has also been Finance Director of WorldCom/MCI Belux, a European subsidiary of one of the world’s largest telecom companies, and CFO and interim CEO of Keyware Technologies. He has also held financial positions at Spector Photo Group, Suez Lyonnaise des Eaux and Unilever.

Eric Halioua (Non-Executive Director) 
Eric Halioua is the managing partner de Carkath sprl. He was the Chief Executive Officer of Promethera Biosciences and is a Board member of the European Biopharmaceutical Enterprises (EBE) and of the Strategy Committee of Innobiochips (Lille). Mr Halioua previously co-founded two biotechnology companies, Myosix and Murigenetics and was a Board Member of the French public biotechnology company Vivalis. Before that he was principal of the international life sciences practice of Arthur D. Little based in Paris and Boston for 11 years. Mr Halioua also worked as a strategic marketing manager for the “Centre Européen de Bioprospective” and as project leader in the corporate R&D centre of Zeneca in UK."

Hervé de Radiguès (Non-Executive Director)
With his Civil Engineer degree at the UCLeuven, Hervé de Radiguès started his professional activities in the chemical industries. After a few years, he choose to become an industrial entrepreneur by acquiring and developing different companies in the plastic injection sector. In 2002, reorienting his activities, he launched companies specialised in the distribution of technical parts for the Telecom, Electricity and Gaz industries. He studied the new bio-medical applications and has invested in some companies specialised in this sector.

François Fontaine (Non-Executive Director)
François Fontaine holds a law degree from the Université Libre de Bruxelles and he is a specialist in Tax affairs. He was counsel in various public institutions and cabinet. He is currently general counsel to the Federal Holding and Investment Company (SFPI)-FPIM. SFPI is focusing its investments on innovative Belgian Companies, hoping to contribute to their financial and societal success story. François is also Board member of several companies including biotechs.

Latest News

Bioxodes’ antithrombotic meets development milestones - Company to launch Series A investment round to bring product to the clinic

Marche-en-Famenne, Belgium – Bioxodes SA, the Belgian-based start-up developing pharmaceutical products ...
Read more